Viking Therapeutics, Inc. (VKTX) stock
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.88+0.08 (+0.30%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Viking Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Viking Therapeutics's enterprise value was $2.82B on Nov 11, 2026, against $3.42B a year earlier. Over the last 5 years it ranged from -$15.87M to $7.85B, with a median of $2.23B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.82B | -13.1% |
| 2025 | Dec 31, 2025 | $3.24B | -8.8% |
| 2024 | Dec 31, 2024 | $3.55B | +139.3% |
| 2023 | Dec 29, 2023 | $1.49B | +162.5% |
| 2022 | Dec 30, 2022 | $565.85M | +293.6% |
| 2021 | Dec 31, 2021 | $143.75M | -7.4% |
| 2020 | Dec 31, 2020 | $155.24M | -46.7% |
| 2019 | Dec 31, 2019 | $291.42M | +20.8% |
| 2018 | Dec 31, 2018 | $241.17M | +113.2% |
| 2017 | Dec 29, 2017 | $113.14M | +448.6% |
| 2016 | Dec 30, 2016 | $20.62M | -34.0% |
| 2015 | Dec 31, 2015 | $31.22M | – |
See a number that looks wrong?